Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.56 |
| ▸ | ME2 | P23368 | 1/20 | 0.56 |
| ▸ | ME1 | P48163 | 1/20 | 0.56 |
| ▸ | ME3 | Q16798 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16707625 | 0.95 | MAPT (0.74) | HCAR2MAPTNPSR1ALDH1A1LMNA | |
| SCHEMBL3785663 | 0.85 | MAPT (0.67) | HCAR2MAPTNPSR1ALDH1A1LMNA | |
| SCHEMBL16707623 | 0.84 | LMNA (0.67) | HCAR2MAPTNPSR1ALDH1A1LMNA | |
| SCHEMBL13666098 | 0.84 | HCAR2 (1.00) | HCAR2MAPTNPSR1ALDH1A1LMNA | |
| SCHEMBL16707629 | 0.83 | LMNA (0.69) | HCAR2MAPTNPSR1ALDH1A1LMNA | |
| SCHEMBL16707675 | 0.83 | HCAR2 (0.52) | HCAR2MAPTNPSR1ALDH1A1LMNA | |
| SCHEMBL16707635 | 0.83 | LMNA (0.58) | MAPTNPSR1ALDH1A1LMNAKDM4E | |
| SCHEMBL17029143 | 0.81 | LMNA (0.80) | HCAR2MAPTNPSR1ALDH1A1LMNA | |
| SCHEMBL16707638 | 0.81 | LMNA (0.67) | HCAR2MAPTNPSR1ALDH1A1LMNA | |
| SCHEMBL16707633 | 0.81 | LMNA (0.78) | HCAR2MAPTNPSR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068774-B1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2019-12-25 | — | — | EP | disclosed |
| US-10364228-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180044300-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20180044300-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-9758489-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758489-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20150315159-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315159-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9115113-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115113-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| WO-2015073774-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20150132258-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC., | 2015-05-14 | — | — | US | disclosed |
| US-20150132258-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC., | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315159-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | HCAR2 1758/4885MAPT 4757/4885NPSR1 3654/4885 |
| US-10364228-B2 | Azepane derivatives and methods of treating hepatitis B infections | HAVCR2, HDGF, AZI2 | HCAR2 1758/4885MAPT 4757/4885NPSR1 3654/4885 |
| US-20180044300-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | HCAR2 1758/4885MAPT 4757/4885NPSR1 3654/4885 |
| US-20150132258-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | HCAR2 1758/4885MAPT 4757/4885NPSR1 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.